Browse > Article
http://dx.doi.org/10.17555/jvc.2021.02.38.1.16

Assessment of Vertebral Left Atrial Size and C-reactive Protein in Dogs With Myxomatous Mitral Valve Disease  

Hwang, Sun-Hwee (College of Veterinary Medicine, Chungnam National University)
Song, Kun Ho (College of Veterinary Medicine, Chungnam National University)
Publication Information
Journal of Veterinary Clinics / v.38, no.1, 2021 , pp. 16-20 More about this Journal
Abstract
Recently, a new method of evaluating left atrial size called vertebral left atrial size (VLAS) was introduced in dogs. Total 155 dogs were examined at the Veterinary Medical Teaching Hospital of Chungnam National University. In this study, myxomatous mitral valve disease (MMVD) stage and VLAS showed a significant correlation in those dogs. Also, the relationship between C-reactive protein (CRP) and VLAS has yet to be examined. We found a strong positive correlation between VLAS and CRP-a significant increase in CRP was observed with increasing VLAS values. Thus, it would be beneficial to measure VLAS besides employing the current radiological and echocardiographic methods when evaluating heart size. Measuring VLAS could be an additional diagnostic tool for diagnosing MMVD in dogs.
Keywords
myxomatous mitral valve disease; vertebral left atrial size; c-reactive protein; dog;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Reynolds CA, Brown DC, Rush JE, Fox PR, Nguyenba TP, Lehmkuhl LB, Gordon SG, Kellihan HB, Stepien RL, Lefbom BK, Meier CK, Oyama MA. Prediction of first onset of congestive heart failure in dogs with degenerative mitral valve disease: the PREDICT cohort study. J Vet Cardiol 2012; 14: 193-202.   DOI
2 Rishniw M, Erb HN. Evaluation of four 2-dimensional echocardiographic methods of assessing left atrial size in dogs. J Vet Intern Med 2000; 14: 429-435.   DOI
3 Serres FJ, Chetboul V, Tissier R, Carlos Sampedrano C, Gouni V, Nicolle AP, Pouchelon JL. Doppler echocardiography-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001-2005). J Am Vet Med Assoc 2006; 229: 1772-1778.   DOI
4 Strohm LE, Visser LC, Chapel EH, Drost WT, Bonagura JD. Two-dimensional, long-axis echocardiographic ratios for assessment of left atrial and ventricular size in dogs. J Vet Cardiol 2018; 20: 330-342.   DOI
5 Vezzosi T, Puccinelli C, Tognetti R, Pelligra T, Citi S. Radiographic vertebral left atrial size: A reference interval study in healthy adult dogs. Vet Radiol Ultrasound 2020; 61: 507-511.
6 Abbott JA. 2008. Acquired valvular disease. In: Manual of canine and feline cardiology. 4th ed. St. Louis: Elsevier Sounders. 2008: 110-138.
7 Borgarelli M, Haggstrom J. Canine degenerative myxomatous mitral valve disease: natural history, clinical presentation and therapy. Vet Clin North Am Small Anim Pract 2010; 40: 651-663.   DOI
8 Andreasova T, Vranova J, Vondrakova D, Sedlackova L, Zakostelska ZJ, Neuzil P, Malek F. Role of biomarkers of cardiac remodeling, myofibrosis, and inflammation in assessment of disease severity in euvolemic patients with chronic stable heart failure. J Int Med Res 2020; 48: 1-12.
9 Apple SM, Menciotti G, Braz-Ruivo L, Crosara S, Haggstrom J, Borgarelli M. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study. Aust Vet J 2016; 94: 324-328.   DOI
10 Borgarelli M, Crosara S, Lamb K, Savarino P, La Rosa G, Tarducci A Haggstrom J. Survival javascript:checkRefBr('', 'next');characteristics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration. J Vet Intern Med 2012; 26: 69-75.   DOI
11 Chetboul V, Tissier R. Echocardiographic assessment of canine degenerative mitral valve disease. J Vet Cardiol 2012; 14: 127-148.   DOI
12 Boswood A, Haggstrom J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmari V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. J Vet Intern Med 2016; 30: 1765-1779.   DOI
13 Buchanan JW, Bucheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995; 206: 194-199.
14 Ceron JJ, Eckersall PD, Martynez-Subiela S. Acute phase proteins in dogs and cats: current knowledge and future perspectives. Vet Clin Pathol 2005; 34: 85-99.   DOI
15 Cornell CC, Kittleson MD, Della Torre P, Haggstrom J, Lombard CW, Pedersen HD, Vollmar A, Wey A. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004; 18: 311-321.   DOI
16 Detweiler DK, Patterson DF. The prevalence and types of cardiovascular disease in dogs. Ann N Y Acad Sci 1965; 127: 481-516.   DOI
17 Diana A, Guglielmini C, Pivetta M, Sanacore A, Di Tommaso M, Lord PF, Cipone M. Radiographic features of cardiogenic pulmonary edema in dogs with mitral regurgitation: 61 cases (1998-2007). J Am Vet Med Assoc 2009; 235: 1058-1063.   DOI
18 Domanjko Petric A, Lukman T, Verk B, Nemec Svete A. Systemic inflammation in dogs with advanced-stage heart failure. Acta Vet Scand 2018; 60: 20.   DOI
19 Haggstrom J, Lord PF, Hoglund K, Ljungvall I, Jons O, Kvart C, Hansson K. Short-term h emodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure. J Vet Intern Med 2013; 27: 1452-1462.   DOI
20 Elster SK, Braunwald E, Wood HF. A study of C-reactive protein in the serum of patients with congestive heart failure. Am Heart J 1956; 51: 533-541.   DOI
21 Keene BW, Atkins CE, Bonagura JD, Fox PR, Haggstrom J, Fuentes VL, Oyama MA, Rush JE, Stepien R, Uechi M. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med 2019; 33: 1127-1140.   DOI
22 Kim SH, Seo KW, Song KH. An assessment of vertebral left atrial size in relation to the progress of myxomatous mitral valve disease in dogs. J Vet Clin 2020; 37: 9-14.   DOI
23 Lamb CR, Wikeley H, Boswood A, Pfeiffer DU. Use of breed-specific ranges for the vertebral heart scale as an aid to the radiographic diagnosis of cardiac disease in dogs. Vet Rec 2001; 148: 707-711.   DOI
24 Malcolm EL, Visser LC, Phillips KL, Johnson LR. Diagnostic value of vertebral left atrial size as determined from thoracic radiographs for assessment of left atrial size in dogs with myxomatous mitral valve disease. J Am Vet Med Assoc 2018; 253: 1038-1045.   DOI
25 Mikawa S, Nagakawa M, Ogi H, Akabane R, Koyama Y, Sakatani A, Ogawa M, Miyakawa H, Shigemoto J, Tokuriki T, Toda N, Miyagawa Y, Takemura N. Use of vertebral left atrial size for staging of dogs with myxomatous valve disease. J Vet Cardiol 2020; 30: 92-99.   DOI
26 Reimann MJ, Ljungvall I, Hillstrom A, Moller JE, Hagman R, Falk T, Hoglund K, Haggstrom J, Olsen LH. Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease. Vet J 2016; 209: 113-118.   DOI